Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $60.22.

Several research firms have recently commented on CLDX. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Finally, UBS Group initiated coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 price target on the stock.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLDX. EverSource Wealth Advisors LLC lifted its stake in Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares during the last quarter. KBC Group NV lifted its stake in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Headlands Technologies LLC bought a new stake in Celldex Therapeutics during the fourth quarter worth $81,000. AlphaQuest LLC lifted its stake in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in Celldex Therapeutics during the fourth quarter worth $121,000.

Celldex Therapeutics Trading Down 0.6 %

Celldex Therapeutics stock opened at $22.46 on Friday. Celldex Therapeutics has a 12 month low of $20.91 and a 12 month high of $53.18. The stock’s 50 day moving average is $24.33 and its 200-day moving average is $29.37. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of -8.74 and a beta of 1.60.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.